Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors; Cell and gene therapy CEOs share survival strategies amid biotech slump

Taking stock of the drug industry, from the lab to the medicine chest

October 16, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Teva sues Colorado over 'unconstitutional' program to lower cost of epinephrine injectors Colorado lawmakers, who estimate 500,000 residents experience severe food allergies, modeled the law on another that caps the cost of insulin By Ed Silverman STAT+ | Cell and gene therapy CEOs share survival strategies amid biotech slump The candid conversation provided a glimpse into discussions happening across the life science industry as biotech markets continue a slump. By Jonathan Wosen Opinion: Doctors — and patients — must seek alternatives to long-term steroids Loss of musculature, psychosis, water retention, weight gain — the side effects of staying on steroids for years can be debilitating. By Judy Hoffstein Adobe STAT+ | What to know about this year's Medicare open enrollment period Insurance brokers and experts expect people will continue to gravitate toward Medicare Advantage, despite those plans' flaws. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser